Aduro BioTech Seals $19.25M
Clinical-stage immunotherapy company Aduro BioTech has closed on $19.25 million in Series B financing. Morningside Ventures contributed to the round, in addition to other unnamed investors. Stephanie O’Brien will represent Morningside on Aduro’s board. The new funding will help Berkeley, Calif.-based Aduro continue development and trials of its lead cancer vaccine.
20 April 2011•3 mins read
